[Translated article] Checklist for the pharmaceutical care of patients with interstitial lung disease (CheckEPID): A Delphi-based consensus.

Objective: To develop a checklist to facilitate pharmaceutical care for patients with interstitial lung disease who require or are undergoing treatment with antifibrotic drugs.
Method: Five hospital pharmacists developed an initial list of 37 items divided into 4 blocks: (1) First visit, which included general patient data and data from the first treatment; (2) follow-up visits, assessing aspects of the follow-up of the treatment with nintedanib or pirfenidone; (3) telepharmacy, consisting of the evaluation of the inclusion of patients in a program of this type, course of the disease, and identification of the contact with the pharmacy service; (4) non-pharmacological treatment and patient information. To decide its potential inclusion in the checklist, 2 rounds of the Delphi were carried out in which the panelists had to assess the degree of agreement of each proposed item according to its "utility", which was the determining criterion for its inclusion, and its "applicability".
Results: Forty-eight hospital pharmacists were contacted, 30 (63%) agreed in writing to participate, 28 (58%) completed the first round of the Delphi, and 27 (56%) completed the second round. After the first round of the Delphi, the questionnaire was amended and comprised 40 items. Of the 40 items evaluated after the 2 rounds of the Delphi, there were 2 that, based on utility, the participants did not reach consensus for inclusion in the checklist: the one referring to "History of surgical intervention, specifically abdominal surgery in the last 4 weeks" (finally kept on the checklist due to its involvement in the indication of nintedanib) and to make recommendations on "Relaxation". No consensus was reached on their applicability for 2 of the items: "Patient stratification according to the Spanish Society of Hospital Pharmacy (SEFH) chronic patient model" and "Collection of Results Reported by the Patient".
Conclusions: The management of patients with ILD and/or pulmonary fibrosis is complex and requires a multidisciplinary approach where the hospital pharmacist plays a key role, especially, although not only, in monitoring drug treatment. We believe that this checklist can contribute from pharmaceutical care to improving the integrated care of patients with ILD who require or are undergoing treatment with antifibrotic drugs.
Competing Interests: Conflicts of interest Marta Calvin Lamas has received funding for scientific training, talks, or scientific advice from the following pharmaceutical companies: AstraZeneca, GlaxoSmithKline, CSL Behring, and Boehringer Ingelheim. Miguel Ángel Calleja Hernández has received funding for medical training, conference presentations, and research from the following pharmaceutical companies: Abbvie, Alexion, Almirall, Amgen, Astellas, AstraZeneca, Bayer, Biogen, Boehringer, Clovis, Genzyme, GSK, Grunenthal, Incyte, Janssen, Jazz, Kyowa, Lilly, Merck, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Seagen, Takeda, TEVA, UCB, and Viiv. Emilio Monte-Boquet has received honorariums or funding from various companies, such as Abbott/Abbvie, Amgen, Astellas, Astra Zeneca, Baxalta, Bayer, Biogen, Bristol-Myers Squibb, Celgene, Chiesi, Eisai, Fresenius, Gilead, GSK, Ipsen, Janssen, Leo Pharma, Lilly, MSD, Merck-Serono, Novartis, Pfizer, Roche, Sanofi, Shire, Theramex, UCB, and ViiV for his participation in education, training, and research projects. Miguel Ángel Rodríguez Sagrado has been remunerated for activities for Abbvie, Advanz, Astellas, Amgen, Astra Zeneca, Biogen, Boehringer Ingelheim, Galapagos, Gilead, GSK, Intercept, Janssen, Leo Pharma, Lundbeck, MerckSerono, MSD, Novartis, Roche, Sandoz, Serono, Tesaro, UCB, Vertex and ViiV. The sponsors have not influenced, other than formal aspects, the design and communication of the scientific results and talks. Pere Ventayol has received funding for medical training, giving presentations, and conducting basic research from the following pharmaceutical companies: Sanofi-Genzyme, Janssen, Gilead, Kern, Teva, and Boehringer Ingelheim.
(Copyright © 2023 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Publicado por Elsevier España, S.L.U. All rights reserved.)